Bacon v. STIEFEL LABORATORIES, INC.

677 F. Supp. 2d 1331, 48 Employee Benefits Cas. (BNA) 2703, 2010 U.S. Dist. LEXIS 1186, 2010 WL 54753
CourtDistrict Court, S.D. Florida
DecidedJanuary 4, 2010
DocketCase 09-21871-CV
StatusPublished
Cited by5 cases

This text of 677 F. Supp. 2d 1331 (Bacon v. STIEFEL LABORATORIES, INC.) is published on Counsel Stack Legal Research, covering District Court, S.D. Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Bacon v. STIEFEL LABORATORIES, INC., 677 F. Supp. 2d 1331, 48 Employee Benefits Cas. (BNA) 2703, 2010 U.S. Dist. LEXIS 1186, 2010 WL 54753 (S.D. Fla. 2010).

Opinion

ORDER GRANTING MOTIONS TO DISMISS IN PART

JAMES LAWRENCE KING, District Judge.

THIS CAUSE comes before the Court upon two motions to dismiss. One was *1336 filed by Stiefel Laboratories, Inc., Charles W. Stiefel, Brent D. Stiefel, Todd Steiefel, Lodewijk de Vink, Matt S. Pattullo, and the Committee Members (collectively, the “Stiefel Defendants”) (DE #21), and one was filed by Terrence N. Bogush and Bogush & Grady, LLP (collectively, the “Bogush Defendants”) (DE # 25). After careful consideration and for the reasons detailed below, the Court determines that both motions should be granted in part.

I. Factual Background

The Complaint (DE # 1) sets forth the following allegations. Plaintiffs are former employees of defendant Stiefel Laboratories, Inc. (“the Company”). They were participants in the Employees’ Stock Bonus Plan (“the Plan”), which allows employees to own stock in the Company and participate in its growth. 1 Under the original terms of the Plan, the participants could not sell, trade, or redeem their shares unless they separated from the company, at which time they had the right to “put” their shares to Company. That is, they had the right to demand that the Company purchase their shares, and the Company had a duty to buy them within a certain period of time.

The Plan is controlled and managed by a Committee, a Trustee, and a Plan Administrator. The Committee members and the Trustee are appointed by the Company’s board of directors (the Trustee is currently defendant Charles W. Stiefel, the Company’s CEO and chairman of the board), and the Plan Administrator is the Committee itself, although the Committee has delegated its duties as Plan Administrator to defendant Matt S. Pattullo. Under the terms of the Plan, it is the Trustee’s responsibility to retain a qualified independent appraiser to determine the fair market value of the Plan stock. Those valuations have been performed by the Bogush Defendants.

Beginning in 2007, the Stiefel Defendants engaged in a series of actions that Plaintiffs claim amount to a scheme to force employees to sell their shares back to the Company at a below-market price, while simultaneously planning to sell the Company at a much higher price than was offered to Plaintiffs. For years, the Company has maintained its stance that it wishes to remain a family-controlled operation. Indeed, on March 8, 2007, an article appeared in the Miami Herald stating that the Company’s CEO, Charles W. Stiefel, had said that the Company had no plans go public. However, things began to appear otherwise when, in August 2007, the Blackstone Group, an asset-management company that specializes in taking companies public, invested $500 million into the Company and received in return a new class of stock worth approximately $60,000 per share and a seat on the Company’s board of directors. Nonetheless, another Herald article on August 10, 2007 reported that the Company stressed it had no plans to go public.

In fact, sometime in November 2008, the Company began to discuss with potential buyers the possible sale of the Company. Then, on November 21, 2008, the Company sent out its regular notice to Plan participants, reporting that the price of the stock — as calculated by an independent appraiser — was $16,469 per share. However, this communication also notified Plan participants that, as of January 1, 2009, the Plan was being terminated and merged into the Company 401(k) plan. Moreover, the communication stated that, for the first time in the Company’s history, Plan participants were being given the option to “diversify” their Company shares by exercis *1337 ing a “put” option — that is, an option to sell their shares back to the Company at the current price. This option could only be exercised during February 2009.

On December 9, 2008, the Company terminated several of its employees, forcing them to exercise their “put” options immediately. On December 18, 2008, Plaintiff Popp elected to exercise the “put” option and sell his shares back to the Company at the reported price. The Company eventually purchased his shares during the February 2009 diversification window. On December 22, 2008, Charles Stiefel, the Company’s CEO, met with the CEO of a potential buyer to discuss merger options. On that same date, the Company sent out another notice, reminding the Plan participants of their option to diversify.

During January 2009, Plaintiff Bacon elected to exercise the “put” option and sell his shares back to the Company at the reported price. As with Plaintiff Popp, the Company eventually purchased his shares during the February 2009 diversification window. By January 2009, merger discussions had progressed to the point where five companies had indicated an interest in acquiring the Company. Indeed, in February 2009, the Company’s management team met with managers from four or five other companies to discuss merger plans. On February 13, representatives from GlaxoSmithKline (“Glaxo”), a potential buyer, attended a Company presentation. On March 20, the Wall Street Journal reported that the Company was considering selling to a potential buyer for $3-4 billion. On March 24, Glaxo and another company submitted purchase bids to the Company. On April 17-19, the Company met with Glaxo to negotiate the final merger agreement, which was signed on April 20. Finally, on April 24, the Company notified its shareholders of the merger, in which Glaxo acquired the Company stock for $68,515.29 per share.

II. Discussion

Plaintiffs filed the Complaint in this case on July 7, 2009, asserting various causes of action. Count 1 alleges Breach of Fiduciary Duty under the Employee Retirement Income Security Act (“ERISA”), 29 U.S.C. § 1101 et seq., against the Stiefel Defendants; Count 2 alleges Breach of Co-Fiduciary Duty under ERISA against the Stiefel Defendants; Count 3 alleges a prohibited transaction under ERISA against the Stiefel Defendants; Count 4 alleges securities fraud under the Securities Exchange Act of 1934 and Rule 10b-5 against the Company and Charles W. Stiefel; Count 5 alleges a violation of the Florida Securities Act, Fla. Stat. § 517.301, against the Company and Charles W. Stiefel; Count 6 alleges accounting malpractice against the Bogush Defendants; and Count 7 alleges common law Breach of Fiduciary Duty against the defendants who are members of the Company board of directors. The Stiefel Defendants have collectively moved to dismiss Counts 1 through 5 and Count 7 (DE #21), and the Bogush Defendants have moved to dismiss Count 6 (DE # 25). The Court will address each argument in turn.

A. The Stiefel Defendants’ Motion to Dismiss

1. Exhaustion of Administrative Remedies Under ERISA

The Stiefel Defendants first argue that all ERISA counts (C aunts 1, 2, and 3) should be dismissed because Plaintiffs have failed to exhaust their administrative remedies.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Finnerty v. Stiefel Laboratories, Inc.
900 F. Supp. 2d 1317 (S.D. Florida, 2012)
Schwade v. Total Plastics, Inc.
837 F. Supp. 2d 1255 (M.D. Florida, 2011)
MacDonald v. SUMMIT ORTHOPEDICS, LTD.
681 F. Supp. 2d 1019 (D. Minnesota, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
677 F. Supp. 2d 1331, 48 Employee Benefits Cas. (BNA) 2703, 2010 U.S. Dist. LEXIS 1186, 2010 WL 54753, Counsel Stack Legal Research, https://law.counselstack.com/opinion/bacon-v-stiefel-laboratories-inc-flsd-2010.